Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
Chemical Research in Toxicology|August 21, 2001
Enzyme-induction dependent bioactivation of troglitazone and troglitazone quinone in vivoJ N Tettey, J L Maggs, W G Rapeport, et al.
Scottish Medical Journal|July 1, 1984
Treatment of intractable neurogenic pain with carbamazepineW G Rapeport, K M Rogers, T D McCubbin, et al.
European Journal of Clinical Investigation|April 1, 1984
Effect of carbamazepine on haem biosynthesis in manW G Rapeport, J C Connell, G G Thompson, et al.
The Journal of Clinical Psychiatry|January 1, 1996
Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepineW G Rapeport, S A Williams, D C Muirhead, et al.
British Journal of Clinical Pharmacology|August 1, 1983
Hepatic enzyme induction and leucocyte delta-aminolaevulinic acid synthase activity: studies with carbamazepineW G Rapeport, G T McInnes, G G Thompson, et al.
British Journal of Clinical Pharmacology|January 1, 1995
The effect of tenidap on the anti-hypertensive efficacy of thiazide diuretics in patients treated for mild to moderate hypertensionW G Rapeport, V C Grimwood, K Korlipara, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
A pharmacokinetic study of granisetron (BRL 43694A), a selective 5-HT3 receptor antagonist: correlation with anti-emetic responseJ Carmichael, B M Cantwell, C M Edwards, et al.
British Journal of Clinical Pharmacology|October 1, 1983
Plasma protein-binding and CSF concentrations of valproic acid in man following acute oral dosingW G Rapeport, A D Mendelow, G French, et al.
British Journal of Cancer|November 1, 1988
Pharmacokinetics and anti-emetic efficacy of BRL43694, a new selective 5HT-3 antagonistJ Cassidy, V Raina, C Lewis, et al.
British Journal of Clinical Pharmacology|January 30, 2004
The influence of diet upon liver function tests and serum lipids in healthy male volunteers resident in a Phase I unitL Purkins, E R Love, M D Eve, et al.
Pageof 3